Journals / İstanbul Journal of Pharmacy / 2019 / Cilt: 49 - Sayı: 1

PPARγ Pro12Ala and C161T polymorphisms, but not PPARα L162V, are associated with osteoporosis risk in Turkish postmenopausal women

Pages
14–19
Publication Date
2019-05-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We suggested that PPARγ Pro12Ala and C161T gene variants might be contributing factors in the development of osteoporosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Stimulation of peroxisome proliferator-activated receptors (PPARs) causes mesenchymal stem cells of the human bone marrow differentiate into adipocytes instead of osteoblasts leading to a decreased number of osteoblasts and a decrease in bone mineral density (BMD).
📊
Key Findings & Data:Thus, PPARs may have impacts on bone metabolism. 224 postmenopausal women (171 osteoporotic and osteopenic, 53 healthy control) were included in this study.
💡
Conclusion & Impact:We suggested that PPARγ Pro12Ala and C161T gene variants might be contributing factors in the development of osteoporosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Peroxisome proliferator-activated receptor · bone mineral density · osteoporosis

Abstract

Stimulation of peroxisome proliferator-activated receptors (PPARs) causes mesenchymal stem cells of the human bone marrow differentiate into adipocytes instead of osteoblasts leading to a decreased number of osteoblasts and a decrease in bone mineral density (BMD). Thus, PPARs may have impacts on bone metabolism. 224 postmenopausal women (171 osteoporotic and osteopenic, 53 healthy control) were included in this study. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and agarose gel electrophoresis techniques were performed to detect PPARα L162V and PPARγ Pro12Ala/C161T polymorphisms. The distribution of PPARγ Pro12Ala genotype and allele frequencies was not statistically different in control and patient (osteopenic+osteoporotic) groups (p>0.05). However, in the patient group, subjects with “Pro12Pro” genotype had lower lumbar spine (L1-L4) BMD values than those with “Ala” allele (p<0.05). The frequency of PPARγ C161T “CC” genotype was higher in the patient group when compared with that in the control group (p<0.05). There were no significant associations between the genotype and allele frequencies of PPARγ C161T/ PPARα L162V and BMD values (p>0.05). We suggested that PPARγ Pro12Ala and C161T gene variants might be contributing factors in the development of osteoporosis.

🔖

Cite This Article

Şirin, Ö. K., AYDOĞAN, H. Y., Uyar, M., CAN, A. (2019). PPARγ Pro12Ala and C161T polymorphisms, but not PPARα L162V, are associated with osteoporosis risk in Turkish postmenopausal women. İstanbul Journal of Pharmacy, Cilt: 49 - Sayı: 1, 14–19. https://ajindex.com/articles/41761

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Abbott BD (2009). Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development. Reprod Toxicol 27: 246-257.
  2. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL (2005). Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146: 1226-1235.
  3. Atug O, Tahan V, Eren F, Tiftikci A, Imeryuz N, Hamzaoglu HO, Tozun N (2008). Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPARgamma) gene in inflammatory bowel disease. J Gastrointestin Liver Dis 17: 433-437.
  4. Canbay E, Kurnaz O, Canbay B, Bugra D, Cakmakoglu B, Bulut T, Yamaner S, Sokucu N, Buyukuncu Y, Yilmaz-Aydogan H (2012). PPAR-gamma Pro12Ala polymorphism and gastric cancer risk in a Turkish population. Asian Pac J Cancer Prev 13: 5875-5878.
  5. Chen ES, Mazzotti DR, Furuya TK, Cendoroglo MS, Ramos LR, Araujo LQ, Burbano RR, Smith Mde A (2010). Association of PPARalpha gene polymorphisms and lipid serum levels in a Brazilian elderly population. Exp Mol Pathol 88: 197-201.
  6. Chia PP, Fan SH, Say YH (2015). Screening of Peroxisome Proliferator-Activated Receptors (PPARs) α, γ and α Gene Polymorphisms for Obesity and Metabolic Syndrome Association in the Multi-Ethnic Malaysian Population. Ethn Dis 25: 383-390.
  7. Cho MC, Lee K, Paik SG, Yoon DY (2008). Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Res 2008: 679137. Do HQ, Nazih H, Luc G, Arveiler D, Ferrières J, Evans A, Amouyel P, Cambien F, Ducimetière P, Bard JM (2009). Influence of cholesteryl ester transfer protein, peroxisome proliferator-activated receptor α, apolipoprotein E, and apolipoprotein A-I polymorphisms on high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I:A-II concentrations: the Prospective Epidemiological Study of Myocardial Infarction study. Metabolism 58: 283-289. Dragojevič J, Ostanek B, Mencej-Bedrač S, Komadina R, Preželj J, Marc J (2011). PPARG gene promoter polymorphism is associated with non-traumatic hip fracture risk in the elderly Slovenian population: a pilot study. Clin Biochem 44: 1085-1089.
  8. Elrod HA, Sun SY (2008). PPARgamma and apoptosis in cancer. PPAR Res 2008: 704165. Erdogan M, Karadeniz M, Eroglu Z, Tezcanli B, Selvi N, Yilmaz C (2007). The relationship of the peroxisome proliferator-activated receptor-gamma 2 exon 2 and exon 6 gene polym